Ceretype Neuromedicine

Ceretype operates at the intersection of neuroimaging, machine learning, clinical research, and therapeutic development. Its stated focus is a scalable fMRI biomarker platform that converts brain-activity data into individual and population-level insights for neuropsychiatric drug discovery and care. The company’s product set spans Brain Insight Report, an individual-level functional brain map; a cloud platform designed to quantify fMRI across scanners and sites; and decision-support metrics covering circuit activity and related measures. That combination gives Ceretype a more translational position than a conventional imaging-research group, because it targets both pharma and biotech development workflows and clinical interpretation. The relevant competitive frame includes neuroimaging biomarker developers, quantitative imaging platforms, and digital tools for precision psychiatry. Ceretype differentiates itself through fMRI standardization, brain-circuitry measures, and founding expertise spanning psychiatric neurobiology, brain imaging, medical devices, regulatory processes, and commercialization. Its $4.35 million disclosed funding base indicates an early-stage position rather than an established commercial imaging platform.

Ceretype’s trajectory shows a progression from formation in 2020 to early financing, technical validation activity, and platform commercialization efforts. The company recorded a $2.25 million seed round on February 2, 2022, followed by a $2 million seed round on January 4, 2023, a $100,000 pre-seed round on March 2, 2023, and an earlier convertible note dated October 6, 2021 with no disclosed amount. Total disclosed funding is $4.35 million across four rounds, with five investors identified. The January 4, 2024 financing announcement marked the clearest public growth milestone, while the March 2024 ISCTM presentation demonstrated an effort to establish standardized and quantifiable fMRI measures. The May 2024 “Multi-echo fMRI reports” patent publication adds evidence of ongoing intellectual-property development. The next observable inflection points would be evidence of recurring pharma or biotech adoption, clinical validation, regulatory progress, or additional financing; none is publicly established here through September 30, 2026.